• Donate
  • Contact

2017-11-29 CSRO Opposes Prescription Benchmark

back to news

CSRO Opposes Efforts to Establish a National Benchmark Plan Standard for Prescription Drugs

Posted: November 29, 2017


The CSRO has submitted comments to CMS expressing concerns with their intent to establish a national benchmark plan standard for prescription drugs in future years. They are concerned that a national benchmark plan standard for prescription drugs amounts to a national formulary, with all of the access problems that entails. As rheumatologists and their patients know from experience in the commercial and Medicare Advantage market, formulary design is not driven by clinical considerations, but rather by rebates and other discounts paid to the various middlemen in the drug supply chain.

CSRO believes patients and their physicians are in the best position to determine the most appropriate pharmaceutical therapies for a multitude of diseases based the clinical evidence and the clinician’s expertise and medical judgement; not the federal government.

Read Letter

We use cookies so that we can remember you and understand how you use our site. If you do not agree with our use of cookies, please change the current settings found in our Cookie Policy. Otherwise, you agree to the use of the cookies as they are currently set. To learn more, please visit our Privacy Policy.